Literature DB >> 18596432

Visual field preservation after multisession cyberknife radiosurgery for perioptic lesions.

John R Adler1, Iris C Gibbs, Putipun Puataweepong, Steven D Chang.   

Abstract

OBJECTIVE: The restricted radiation tolerance of the anterior visual pathways represents a unique challenge for ablating adjacent lesions with single-session radiosurgery. Although preliminary studies have recently demonstrated that multisession radiosurgery for selected perioptic tumors is both safe and effective, the number of patients in these clinical series was modest and the length of follow-up limited. The current retrospective study is intended to help address these shortcomings.
METHODS: Forty-nine consecutive patients with meningioma (n = 27), pituitary adenoma (n = 19), craniopharyngioma (n = 2), or mixed germ cell tumor (n = 1) situated within 2 mm of a "short segment" of the optic apparatus underwent multisession image-guided radiosurgery at Stanford University Medical Center. Thirty-nine of these patients had previous subtotal surgical resection, and six had previously been treated with conventional fractionated radiotherapy (6). CyberKnife radiosurgery was delivered in two to five sessions to an average tumor volume of 7.7 cm3 and a cumulative average marginal dose of 20.3 Gy. Formal visual testing and clinical examinations were performed before treatment and at follow-up intervals beginning at 6 months.
RESULTS: After a mean visual field follow-up of 49 months (range, 6-96 mo), vision was unchanged postradiosurgery in 38 patients, improved in eight (16%), and worse in three (6%). In each instance, visual deterioration was accompanied by tumor progression that ultimately resulted in patient death. However, one of these patients, who had a multiply recurrent adrenocorticotropic hormone-secreting pituitary adenoma, initially experienced early visual loss without significant tumor progression after both a previous course of radiotherapy and three separate sessions of radiosurgery. After a mean magnetic resonance imaging follow-up period of 46 months, tumor volume was stable or smaller in all other cases. Two patients died of unrelated nonbrain causes.
CONCLUSION: Multisession radiosurgery resulted in high rates of tumor control and preservation of visual function in this group of perioptic tumors. Ninety-four percent of patients retained or improved preradiosurgical vision. This intermediate-term experience reinforces the findings from earlier studies that suggested that multisession radiosurgery can be a safe and effective alternative to either surgery or fractionated radiotherapy for selected lesions immediately adjacent to short segments of the optic apparatus.

Entities:  

Year:  2008        PMID: 18596432     DOI: 10.1227/01.neu.0000316277.14748.63

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  14 in total

1.  Hypofractionated stereotactic radiosurgery for large-sized skull base meningiomas.

Authors:  Hyuk-Jin Oh; Young Hyun Cho; Jeong Hoon Kim; Chang Jin Kim; Do Hoon Kwon; Doheui Lee; KyoungJun Yoon
Journal:  J Neurooncol       Date:  2020-07-01       Impact factor: 4.130

Review 2.  Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon.

Authors:  Christopher Salvatore Graffeo; Avital Perry; Michael J Link; David J Daniels
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-19

3.  Clinical outcomes of perioptic tumors treated with hypofractionated stereotactic radiotherapy using CyberKnife® stereotactic radiosurgery.

Authors:  Putipun Puataweepong; Mantana Dhanachai; Ake Hansasuta; Somjai Dangprasert; Chomporn Sitathanee; Rawee Ruangkanchanasetr; Pornpan Yongvithisatid
Journal:  J Neurooncol       Date:  2018-05-30       Impact factor: 4.130

Review 4.  Management of aggressive growth hormone secreting pituitary adenomas.

Authors:  Daniel A Donoho; Namrata Bose; Gabriel Zada; John D Carmichael
Journal:  Pituitary       Date:  2017-02       Impact factor: 4.107

5.  Single and hypofractionated stereotactic radiotherapy with CyberKnife for craniopharyngioma.

Authors:  Hiromitsu Iwata; Koshi Tatewaki; Mitsuhiro Inoue; Naoki Yokota; Yoshimi Baba; Ryutaro Nomura; Yuta Shibamoto; Kengo Sato
Journal:  J Neurooncol       Date:  2011-08-23       Impact factor: 4.130

6.  Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity.

Authors:  Hiromitsu Iwata; Kengo Sato; Koshi Tatewaki; Naoki Yokota; Mitsuhiro Inoue; Yoshimi Baba; Yuta Shibamoto
Journal:  Neuro Oncol       Date:  2011-06-10       Impact factor: 12.300

Review 7.  Unyielding progress: recent advances in the treatment of central nervous system neoplasms with radiosurgery and radiation therapy.

Authors:  Dale Ding; Chun-Po Yen; Robert M Starke; Cheng-Chia Lee; Jason P Sheehan
Journal:  J Neurooncol       Date:  2014-08-14       Impact factor: 4.130

8.  Treatment of pituitary adenomas using radiosurgery and radiotherapy: a single center experience and review of literature.

Authors:  Daniel Q Sun; Jennifer J Cheng; James L Frazier; Sachin Batra; Gary Wand; Lawrence R Kleinberg; Daniele Rigamonti; Alfredo Quinones-Hinojosa; Roberto Salvatori; Michael Lim
Journal:  Neurosurg Rev       Date:  2010-09-14       Impact factor: 3.042

9.  The radiosurgery fractionation quandary: single fraction or hypofractionation?

Authors:  John P Kirkpatrick; Scott G Soltys; Simon S Lo; Kathryn Beal; Dennis C Shrieve; Paul D Brown
Journal:  Neuro Oncol       Date:  2017-04-01       Impact factor: 12.300

10.  Quantifying the effects of positional uncertainties and estimating margins for Gamma-Knife® fractionated radiosurgery of large brain metastases.

Authors:  Béatrice Reiner; Peter Bownes; David L Buckley; David I Thwaites
Journal:  J Radiosurg SBRT       Date:  2017
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.